Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anand Modadugu

Interventional Pain Medicine Lexington, KY Medical Doctor

NPI 1669674206 CMS profile 30926

2416 Regency Road, Lexington, KY 40503

Open in the dashboard

General payments

$11,560

143 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anand Modadugu of Lexington, KY is reported in the CMS Open Payments database as having received $11,560 across 143 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,699 57
2024 General $1,732 22
2023 General $1,934 23
2022 General $617 21
2021 General $328 4
2020 General $146 4
2019 General $1,105 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anand Modadugu
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Anand Modadugu were reported at $5,699. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Anand Modadugu Interventional Pain Medicine median Middle half National median
2019 $1,105 $684 $216–$2,079 $163
2020 $146 $382 $122–$1,109 $114
2021 $328 $552 $167–$1,554 $132
2022 $617 $605 $187–$1,924 $149
2023 $1,934 $671 $195–$1,915 $160
2024 $1,732 $684 $206–$1,837 $164
2025 $5,699 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,205 18 payments
  2. Medtronic, Inc. $2,126 32 payments
  3. Spinal Simplicity, LLC $975 8 payments
  4. Medtronic USA, Inc. $960 8 payments
  5. Bioventus LLC $779 5 payments
  6. Boston Scientific Corporation $702 12 payments
  7. Stryker Corporation $640 4 payments
  8. Curonix LLC $581 5 payments
  9. SPR Therapeutics, Inc $523 5 payments
  10. Foundation Fusion Solutions, LLC $509 2 payments
  11. Other $1,559 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $6,977 31 payments
  2. Food and Beverage $4,583 112 payments
Products named General payments · program years 2019–2025
  1. KYPHON EXPRESS II KYPHOPAK TRAY $1,806 15 payments
  2. IonicRF $1,046 4 payments
  3. HA MINUTEMAN G3-R $975 8 payments
  4. PROCLAIM $885 7 payments
  5. ADAPTIVESTIM $782 3 payments
  6. Stimrouter Implantable Kit $779 5 payments
  7. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $581 5 payments
  8. MILD DEVICE KIT $554 2 payments
  9. WaveWriter Alpha Prime 16 $543 9 payments
  10. SPRINT PNS System $523 5 payments
  11. Other $2,371 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

7,448

Median for Internal Medicine: 777

Drug cost

$144,425

Median for Internal Medicine: $73,373

Branded share of claims

53.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 2,748 $47,796
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,161 $23,374
Relistor Methylnaltrexone Bromide Brand 11 $19,083
Gabapentin Generic 1,737 $18,352
Pregabalin Generic 332 $9,821
Tramadol Hcl Generic 383 $5,985
Methadone Hcl Generic 244 $3,711
Diclofenac Sodium Generic 178 $3,686
Oxycodone Hcl Generic 176 $3,364
Lidocaine Generic 23 $3,112

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$53,873

Of which drugs: $68

Medicare patients

136

Average age 69

Services billed

1,051

82 women, 54 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
COPD 39%
Diabetes 38%
Depression 35%
Ischemic heart disease 29%
Chronic kidney disease 23%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $66
$66 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $14
$14 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

143 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record